Roberto Pili, MD

Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.

Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.